Cover Image
市場調查報告書

靜脈注射免疫球蛋白 (IVIg) 的全球市場

Intravenous Immunoglobulin (IVIg)

出版商 Global Industry Analysts, Inc. 商品編碼 252361
出版日期 內容資訊 英文 165 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
靜脈注射免疫球蛋白 (IVIg) 的全球市場 Intravenous Immunoglobulin (IVIg)
出版日期: 2015年01月01日 內容資訊: 英文 165 Pages
簡介

本報告提供全球靜脈注射免疫球蛋白(IVIg)市場相關調查、各地區趨勢、2013年∼2020年的預測、市場參與企業簡介等彙整資料。

第1章 簡介、調查方法、產品定義

第2章 摘要整理

  • 產業概要
    • 靜脈注射免疫球蛋白
    • FDA已經過核准及非標籤藥物的靜脈注射免疫球蛋白治療方法清單
    • 各地區市場
    • 推動成長要素和市場課題
    • 競爭模式
    • 全球大企業所提供的IVIg產品
  • 市場趨勢
  • 血漿蛋白質:概要
  • 治療概要
    • 免疫球蛋白概要
    • IVIg和SCIg
    • 產品及治療的成本
    • 副作用
    • 治療頻率
    • 安全性
    • 患者對治療的反應
    • 治療部位
    • IVIg治療的簡介
    • 血管內免疫球蛋白
    • IVIg作用機制 其他
  • 法律上的認證
  • 產品創新/引進
  • 近幾年的產業活動
  • 全球參與企業
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
  • 亞太地區
    • 澳洲
    • 中國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7776

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million and in Kilograms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -

Baxter International, Inc.
Beijing Tiantan Biological Products Co., Ltd.
Bharat Serums and Vaccines Limited
Biotest AG
China Biologic Products, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Intravenous Immunoglobulin - A Proliferating Biologic
  • List of FDA-Approved and Off-Label Uses of Intravenous Immunoglobulin Therapy
  • Regional Market Perspective
    • Table 1: Global Intravenous Immunoglobulin Market by Geographic Region (2014): Percentage Share Breakdown of Volume Sales for North America, Europe, Asia-Pacific (incl.Japan), Latin America, and Rest of World (includes corresponding Graph/Chart)
  • Growth Drivers and Market Challenges
  • Competitive Scenario
    • Table 2: Global Intravenous Immunoglobulin Market by Leading Player (2013): Percentage Market Share Breakdown of Value Sales for Baxter, Biotest, CSL, Grifols, Kedrion, Non-Profit Organizations, Octapharma, and Other Commercial Organizations (includes corresponding Graph/Chart)
  • IVIg Products Offered by Global Leading Players (2013)

2. MARKET TRENDS

  • Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
  • Subcutaneous IG Formulations Gain Therapeutic Foothold
    • Table 3: Global Subcutaneous Immunoglobulin Market: 2013-2020 (includes corresponding Graph/Chart)
    • Table 4: Global SCIG Market by Leading Player (2014): Percentage Market Share Breakdown of Revenue for Baxter, CSL, and Grifols (includes corresponding Graph/Chart)
    • Table 5: Global SCIG Sales for Primary Immunodeficiency Disorders (PID) by Leading Player (2014): Percentage Market Share Breakdown of Sales for Baxter, CSL, and Grifols (includes corresponding Graph/Chart)
    • Table 6: Global SCIG Sales for Chronic Inflammatory Demyelinating Polyneuropathy by Leading Player: Percentage Market Share Breakdown of Sales for Baxter, CSL, and Grifols (2014) (includes corresponding Graph/Chart)
  • Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead
  • IVIg Treatment for Alzheimer's Hindered by Unsuccessful Clinical Trials
  • Synthetic Replacements to IVIg Therapy
  • IVIg Therapy - Home-based vs. Outpatient Settings
  • IVIg Prices to Remain Strong both in the US and Outside the US
    • Table 7: Average IVIg Product Price in the US during the Years 2010-2014 (US$/gram) (includes corresponding Graph/Chart)
  • Per Capita Consumption Rate Varies Across Countries
    • Table 8: Global Intravenous Immunoglobulin Market (2013): Per Capita Consumption for Select Countries (in Kilograms per Million Inhabitants) (includes corresponding Graph/Chart)
  • Baxter's Gammagard, the Leading Immunoglobulin Product in the US
  • Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth
  • Favorable Reimbursement and High Usage make US the Largest Consumer of Immunoglobulins Worldwide
  • Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
  • Aging Global Population: Major Opportunity Indicator
    • Table 9: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 10: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
  • Improving Healthcare Expenditure to Foster Growth
    • Table 11: Top 20 Countries with the Highest Healthcare Spending as a Percentage of GDP: 2012 (includes corresponding Graph/Chart)

3. PLASMA PROTEINS - AN OVERVIEW

  • Plasma Market Witnesses Surging Demand
    • Table 12: Global Plasma Market by Product (2013): Percentage Share Breakdown of Sales for A1PI, Coagulation Factor IX, Coagulation Factor VIII, Fibrinogen, Human Albumin, Ig for Intramuscular Injection, IVIg, Prothrombin Complex, and Specific Ig (includes corresponding Graph/Chart)
    • Table 13: Global Market for Plasma Proteins by Geographic Region (2013): Percentage Breakdown of Value Sales for Asia-Pacific, Europe, Latin America, North America, and Rest of World (includes corresponding Graph/Chart)
    • Table 14: Global Plasma Products Market by Leading Player (2013): Percentage Market Share Breakdown of Value Sales for Baxter, Biotest, CSL, Grifols, Octapharma, and Others (includes corresponding Graph/Chart)
  • Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins

4. THERAPY OVERVIEW

  • Immunoglobulins Overview
    • Table 15: Global Immunoglobulin Usage by Indication (2013): Percentage Share Breakdown of Volume Usage for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Disorders (PID), Other Neuroimmunologic Disorders, Immune Thrombocytopenic Purpura (ITP) and Others (includes corresponding Graph/Chart)
    • Table 16: Global Immunoglobulin (IVIg & SCIg) Market (2013): Percentage Breakdown of Volume Share by Medical Specialty (includes corresponding Graph/Chart)
  • IVIg and SCIg: A Face-off!
  • Cost of Product and Treatment
  • Side-Effects
  • Frequency of Treatment
  • Safety Considerations
  • Patient Response to Treatment Varies
  • Site of Care
  • IVIg Therapy Introduction
  • Intravenous Immunoglobulin
  • Mechanism of IVIg Action
  • IVIg Dosage and Treatment Response Time
  • Common IVIg Intravenous Dosing Recommendations by Indication
  • Complications and Side Effects of Using IVIg
  • Precautions to be Undertaken
  • Intravenous Immunoglobulin - Indications
  • FDA Approved Indications for IVIg
  • Off-Label Usage of IVIg
    • Select Off-Label Indications for IVIg
  • Applications by Medical Specialty
  • Neurology
  • Hematology
  • Immunology
  • Dermatology
  • Nephrology, Rheumatology, Ophthalmology, and Other Diseases

5. REGULATORY APPROVALS

  • CSL Behring Obtains EC Marketing Approval for Privigen(r) for CIDP Patients
  • CSL Behring Obtains FDA Approval for Privigen(r) to Treat PID and ITP
  • Biotest Pharmaceuticals Obtains FDA Approval for BIVGAM(tm) IVIg
  • Baxter Obtains EC Marketing Approval for HyQvia
  • Green Cross Receives Approval to Commence Phase III Clinical Trials
  • Baxter Bags FDA Approval for GAMMAGARD LIQUID to Treat MMN

6. PRODUCT INNOVATIONS/INTRODUCTIONS

  • Octapharma Canada Introduces Octagam(r)10% in Canada
  • Biotest Introduces BIVIgAM(tm) in the US

7. RECENT INDUSTRY ACTIVITY

  • Emergent BioSolutions Acquires Cangene
  • CMS Begins Evaluation of Payment for In-home IVIG Administration
  • AxelaCare Acquires SCP Specialty Infusion
  • Pfizer to License Gliknik's GL-2045
  • Octapharma Completes Phase II Clinical Trial of Octagam 10% for Alzheimer's
  • Grifols International Establishes New IVIg Purification Facility in Los Angeles
  • Sorrento Therapeutics Secures Global Rights for Using G-MAB(r) Antibody Library Technology to Produce rIVIg
  • Momenta Pharmaceuticals Acquires Sialic Switch Assets of Virdante Pharmaceuticals
  • Grifols' AMBAR Study Integrates Therapeutic Plasmapheresis with Alternating Infusion of IVIg and Albumin for Treatment of Alzheimer's Disease
  • Biotest Publishes Clinical Trial Data Related to New Investigational IVIg Product

8. FOCUS ON SELECT PLAYERS

  • Baxter International, Inc. (US)
  • Beijing Tiantan Biological Products Co., Ltd (China)
  • Bharat Serums and Vaccines Limited (India)
  • Biotest AG (Germany)
  • China Biologic Products, Inc (China)
  • Guizhou Taibang Biological Products Co., Ltd (China)
  • CSL Limited (Australia)
  • CSL Behring LLC (US)
  • Grifols, S.A (Spain)
  • Hualan Biological Engineering Inc. (China)
  • Kedrion S.p.A. (Italy)
  • LFB Group (France)
  • Octapharma AG (Switzerland)
  • OMRIX Biopharmaceuticals Ltd (Israel)
  • Shanghai RAAS Blood Products Co., Ltd. (China)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

9. GLOBAL MARKET PERSPECTIVE

  • Value Analytics
    • Table 17: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 18: World Historic Review for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 19: World 15-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
  • Volume Analytics
    • Table 20: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Consumption Volume in Kilograms for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 21: World Historic Review for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Consumption Volume in Kilograms for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 22: World 15-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Volume Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Favorable Reimbursement and High Usage Make US the Largest Consumer of Immunoglobulins Worldwide
    • Table 23: The US Market for Intravenous Immunoglobulin by Leading Player (2014): Percentage Market Share Breakdown of Volume Sales for Baxter, CSL Behring, Grifols, Kedrion, Octapharma, and Others (includes corresponding Graph/Chart)
    • Table 24: The US Market for Immunoglobulins by Leading Player (2014): Percentage Market Share Breakdown of Value Sales for Gammagard Liquid/Kiovig, Flebogamma/ Gamunex, Privigen/Carimune NF, Octagam and Others (includes corresponding Graph/Chart)
    • Table 25: The US Market for IVIg Products by Indication (2014 & 2020E): Percentage Breakdown of Volume Sales for CIDP, CLL, ITP, MMN, PID, and Other Neurological Diseases (includes corresponding Graph/Chart)
    • Ageing Demographics: A Key Market Driver
    • Table 26: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Intravenous Immunoglobulin Reimbursement Scenario
    • US Market Pricing Analysis
    • Table 27: The US IVIg Pricing by Company & Brand (US$/g): Comparative Analysis of Pricing for 2012, 2013, and 2014 (includes corresponding Graph/Chart)
    • Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
    • US Blood Supply System - A Schematic
    • Regulatory Approvals
    • Product Launch
    • Strategic Corporate Developments
    • Select Major Players
  • B. Market Analytics
    • Value Analytics
    • Table 28: The US Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 29: The US Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 30: The US Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 31: The US Historic Review for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2006 through 2012 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Highest Per Capita Consumption of Intravenous Immunoglobulin
    • Canadian Blood Services - At the Forefront of Blood Collection in Canada
    • Product Launch
  • B. Market Analytics
    • Value Analytics
    • Table 32: Canadian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 33: Canadian Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 34: Canadian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 35: Canadian Historic Review for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2006 through 2012 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Graying Population to Drive Market Growth
    • Table 36: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Value Analytics
    • Table 37: Japanese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 38: Japanese Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 39: Japanese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 40: Japanese Historic Review for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2006 through 2012 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Ageing Population Drives Demand
    • Table 41: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
    • Key Statistics
    • Table 42: European Market for Intravenous Immunoglobulin by Leading Player (2014): Percentage Market Share Breakdown of Volume Sales by Plasma Fractionators for Baxter Healthcare, Biotest, CSL Behring, Grifols, Kedrion, Octapharma, and Others (includes corresponding Graph/Chart)
    • Table 43: European Immunoglobulin (IVIg and SCIg) Per Capita Consumption in Kilograms per Million Inhabitants (2012) (includes corresponding Graph/Chart)
    • European Sub-Q IVIg Product Approvals
    • Regulatory Approvals
  • B. Market Analytics
    • Value Analytics
    • Table 44: European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 45: European Historic Review for Intravenous Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 46: European 15-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 47: European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 48: European Historic Review for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2006 through 2012 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Research Initiative in France
      • High-dose Intravenous Immunoglobulin to Offer Respite for Primary Sjogren's Syndrome Patients
      • LFB Group - A Key Player
  • B. Market Analytics
    • Table 49: French Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 50: French Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Biotest AG - A Key Player
  • B. Market Analytics
    • Table 51: German Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 52: German Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Kedrion S.p.A. - A Key Player
  • B. Market Analytics
    • Table 53: Italian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 54: Italian Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • New Concept to Stimulate Plasma Market: Welsh lood Service Proposes Sale of Blood Plasma
  • B. Market Analytics
    • Table 55: The UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 56: The UK Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Strategic Corporate Development
    • Grifols, S.A - A Key Player
  • B. Market Analytics
    • Table 57: Spanish Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 58: Spanish Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Strategic Corporate Development
    • Octapharma AG (Switzerland) - A Key Player
  • B. Market Analytics
    • Table 59: Rest of European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 60: Rest of European Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Table 61: Asia-Pacific Market for Immunoglobulin (IVIg and SCIg) (2012): Per Capita Consumption (in Kilograms per Million Inhabitants) (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Value Analytics
    • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - Australia, China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 63: Asia-Pacific Historic Review for Intravenous Immunoglobulin by Geographic Region - Australia, China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 64: Asia-Pacific 15-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Revenues for Australia, China and Rest of Asia-Pacific Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 66: Asia-Pacific Historic Review for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2006 through 2012 (includes corresponding Graph/Chart)

5a. AUSTRALIA

  • A. Market Analysis
    • Overview
    • Table 67: Australian IVIg Usage by Main Indications (% of grams used annually) (includes corresponding Graph/Chart)
    • Revised Criteria for Clinical Use of IVIg in Australia
    • Australian Blood Products Market - An Overview
    • Australian Red Cross Blood Service
    • CSL Limited - A Key Player
  • B. Market Analytics
    • Table 68: Australian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 69: Australian Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5b. CHINA

  • A. Market Analysis
    • Unmet Plasma Protein Needs Presents Opportunities
    • Table 70: IVIg Annual Supply in China: 2010- 2013 (includes corresponding Graph/Chart)
    • Table 71: Chinese Market for IVIg Products by Major Player (2013): Percentage Market Share Breakdown of Value Sales for Chengdu, CBPO, Hualan Biological, Shanghai Institute of Biological Products, Shanxi Kangbao, Sichuan Yuanda Shuyang, and Others (includes corresponding Graph/Chart)
    • Select Key Players
  • B. Market Analytics
    • Table 72: Chinese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 73: Chinese Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • Indonesia - An Overview
    • Bharat Serums and Vaccines Ltd (India) - A Key Player
  • B. Market Analytics
    • Table 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 75: Rest of Asia-Pacific Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Overview of the Middle East
    • Iran Attains Self-Sufficiency in Plasma Production
    • OMRIX Biopharmaceuticals Ltd (Israel) - A Key Player
  • B. Market Analytics
    • Value Analytics
    • Table 76: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 77: Rest of World Historic Review for Intravenous Immunoglobulin with Annual Revenue Figures in US$ Million for Years 2006 through 2012(includes corresponding Graph/Chart)
    • Volume Analytics
    • Table 78: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 79: Rest of World Historic Review for Intravenous Immunoglobulin with Annual Consumption Volume in Kilograms for Years 2006 through 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top